高级搜索

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

基于个性化网络标志物的药物推荐方法研究

刘文斌 吴倩 杜玉改 方刚 石晓龙 许鹏

刘文斌, 吴倩, 杜玉改, 方刚, 石晓龙, 许鹏. 基于个性化网络标志物的药物推荐方法研究[J]. 电子与信息学报, 2020, 42(6): 1340-1347. doi: 10.11999/JEIT190837
引用本文: 刘文斌, 吴倩, 杜玉改, 方刚, 石晓龙, 许鹏. 基于个性化网络标志物的药物推荐方法研究[J]. 电子与信息学报, 2020, 42(6): 1340-1347. doi: 10.11999/JEIT190837
Wenbin LIU, Qian WU, Yugai DU, Gang FANG, Xiaolong SHI, Peng XU. Drug Recommendation Based on Individual Specific Biomarkers[J]. Journal of Electronics & Information Technology, 2020, 42(6): 1340-1347. doi: 10.11999/JEIT190837
Citation: Wenbin LIU, Qian WU, Yugai DU, Gang FANG, Xiaolong SHI, Peng XU. Drug Recommendation Based on Individual Specific Biomarkers[J]. Journal of Electronics & Information Technology, 2020, 42(6): 1340-1347. doi: 10.11999/JEIT190837

基于个性化网络标志物的药物推荐方法研究

doi: 10.11999/JEIT190837
基金项目: 国家重点研发计划(2019YFA0706402),国家自然科学基金(61572367, 61573017, 61972107, 61972109)
详细信息
    作者简介:

    刘文斌:男,1969年生,教授,研究方向为生物信息学

    吴倩:女,1994年生,硕士,研究方向为生物信息学

    杜玉改:女,1993年生,硕士,研究方向为生物信息学

    方刚:男,1969年生,教授,研究方向为生物信息学

    石晓龙:男,1975年生,教授,研究方向为生物信息学

    许鹏:男,1986年生,博士后,研究方向为生物信息学

    通讯作者:

    许鹏 gdxupeng@gzhu.edu.cn

  • 中图分类号: TP301

Drug Recommendation Based on Individual Specific Biomarkers

Funds: The National Key R&D Program of China (2019YFA0706402), The National Natural Science Foundation of China (61572367, 61573017, 61972107, 61972109)
  • 摘要: 基于个性化标志物的药物推荐研究,有助于实现个性化用药及推动精准医疗的发展。该文利用基因表达谱数据及蛋白质网络信息,基于基因2维高斯分布方法筛选出个性化网络标志物。进而综合考虑靶基因的重要性和药物的副作用,提出了一种计算药物对个性化标志物影响权重的方法。将该方法应用于肺腺癌、肾透明细胞癌和子宫内膜癌数据集,通过启发式搜索方法,得到每个疾病样本重要药物推荐列表。结果表明,推荐的药物列表在同种癌症不同样本中既存在一致性,也表现出很大的差异性,如药物种类及药物排序差异,这说明个性化药物在疾病治疗中的重要性及必要性。通过从药物数据库中搜索药物组合对疾病治疗的影响作用表明,该文方法筛选得到的许多药物组合对具体疾病治疗具有积极影响,这进一步证明该文基于个性化网络标志物的药物推荐方法的准确性。该文的研究将有效促进精准化医疗的发展。
  • 图  1  癌症个性化网络标志物获取流程

    图  2  3种癌症中药物靶基因数量与药物副作用数量之间的散点图

    图  3  3种癌症中考虑药物副作用和不考虑药物副作用时药物的排名

    图  4  3类癌症得到的候选药物集合在各个样本中的具体分布

    图  5  DrugBank数据库中具有协同作用的药物对在各个样本中的分布情况

    表  1  3种癌症数据集统计信息

    癌症类型样本数量(正常/癌症)
    LUAD609(95/514)
    KIRC602(72/530)
    UCEC578(35/543)
    下载: 导出CSV

    表  2  启发式搜索的迭代过程

     个性化药物推荐算法
     输入:物集合$D = \{ d_1,d_2, ··· ,{d_n}\} $;
        个性化标志物集合$T = \{ t_1,t_2, ··· ,t_m\} $;
     输出:个性化药物推荐列表 (Personalized Drug, PD);
     (1) Initialization: Set $k = 1$;
     (2) DO
     (3) for $i = 1,2, ··· ,n$
     (4) Compute $S\left( {{d_i}} \right)$;
     (5) EndFor
     (6) If S(di) is the maximum among all drugs in $D$ then
     (7) ${\rm{PD}}\left( k \right) = {d_i}$;
     (8) $k = k + 1$;
     (9) EndIf
     (10) Update $D$: Delete di from $D$;
     (11) Update $T$: Delete all targets of ${d_i}$ from $T$;
     (12) WHILE Max(targets number of each drug in $D$)>=6
    下载: 导出CSV
  • SIEGEL R L, MILLER K D, and JEMAL A. Cancer statistics, 2016[J]. CA: A Cancer Journal for Clinicians, 2016, 66(1): 7–30. doi: 10.3322/caac.21332
    TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. CA: A Cancer Journal for Clinicians, 2015, 65(2): 87–108. doi: 10.3322/caac.21262
    WANG Hongwei, SUN Qiang, ZHAO Wenyuan, et al. Individual-level analysis of differential expression of genes and pathways for personalized medicine[J]. Bioinformatics, 2015, 31(1): 62–68. doi: 10.1093/bioinformatics/btu522
    LIU Xiaoping, WANG Yuetong, JI Hongbin, et al. Personalized characterization of diseases using sample-specific networks[J]. Nucleic Acids Research, 2016, 44(22): e164. doi: 10.1093/nar/gkw772
    ZHANG Wanwei, ZENG Tao, and CHEN Luonan. EdgeMarker: Identifying differentially correlated molecule pairs as edge-biomarkers[J]. Journal of Theoretical Biology, 2014, 362: 35–43. doi: 10.1016/j.jtbi.2014.05.041
    YU Xiangtian, ZHANG Jingsong, SUN Shaoyan, et al. Individual-specific edge-network analysis for disease prediction[J]. Nucleic Acids Research, 2017, 45(20): e170. doi: 10.1093/nar/gkx787
    PERLMAN L, GOTTLIEB A, ATIAS N, et al. Combining drug and gene similarity measures for drug-target elucidation[J]. Journal of Computational Biology, 2011, 18(2): 133–145. doi: 10.1089/cmb.2010.0213
    WANG Wenhui, YANG Sen, and LI Jing. Drug Target Predictions Based on Heterogeneous Graph Inference[M]. ALTMAN R B, DUNKER A K, HUNTER L, et al. Biocomputing 2013. Hawaii, USA: World Scientific, 2013: 53-64 doi: 10.1142/9789814447973_0006.
    ZONG Nansu, KIM H, NGO V, et al. Deep mining heterogeneous networks of biomedical linked data to predict novel drug-target associations[J]. Bioinformatics, 2017, 33(15): 2337–2344. doi: 10.1093/bioinformatics/btx160
    SU Junjie, YOON B J, and DOUGHERTY E R. Accurate and reliable cancer classification based on probabilistic inference of pathway activity[J]. PLoS One, 2009, 4(12): e8161. doi: 10.1371/journal.pone.0008161
    TOMCZAK K, CZERWIŃSKA P, and WIZNEROWICZ M. The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge[J]. Contemporary Oncology (Poznan, Poland) , 2015, 19(1A): A68–A77. doi: 10.5114/wo.2014.47136
    SZKLARCZYK D, MORRIS J H, COOK H, et al. The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible[J]. Nucleic Acids Research, 2017, 45(D1): D362–D368. doi: 10.1093/nar/gkw937
    WISHART D S, FEUNANG Y D, GUO A C, et al. DrugBank 5.0: A major update to the DrugBank database for 2018[J]. Nucleic Acids Research, 2018, 46(D1): D1074–D1082. doi: 10.1093/nar/gkx1037
    GRIFFITH M, GRIFFITH O L, COFFMAN A C, et al. DGIdb: Mining the druggable genome[J]. Nature Methods, 2013, 10(12): 1209–1210. doi: 10.1038/nmeth.2689
    李玉博, 陈邈. 几乎完备高斯整数序列构造法[J]. 电子与信息学报, 2018, 40(7): 1752–1758. doi: 10.11999/JEIT170844

    LI Yubo and CHEN Miao. Construction of nearly perfect gaussian integer sequences[J]. Journal of Electronics &Information Technology, 2018, 40(7): 1752–1758. doi: 10.11999/JEIT170844
    陈曦, 张坤. 一种基于树增强朴素贝叶斯的分类器学习方法[J]. 电子与信息学报, 2019, 41(8): 2001–2008. doi: 10.11999/JEIT180886

    CHEN Xi and ZHANG Kun. A classifier learning method based on tree-augmented naïve bayes[J]. Journal of Electronics &Information Technology, 2019, 41(8): 2001–2008. doi: 10.11999/JEIT180886
    FANUCCHI M P, FOSSELLA F V, BELT R, et al. Randomized phase ii study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer[J]. Journal of Clinical Oncology, 2006, 24(31): 5025–5033. doi: 10.1200/JCO.2006.06.1853
    DAVIES A M, RUEL C, LARA P N, et al. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: A california cancer consortium phase I study[J]. Journal of Thoracic Oncology, 2008, 3(1): 68–74. doi: 10.1097/JTO.0b013e31815e8b88
    DAVIES A M, CHANSKY K, LARA Jr P N, et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II southwest oncology group study (S0339)[J]. Journal of Thoracic Oncology, 2009, 4(1): 87–92. doi: 10.1097/JTO.0b013e3181915052
    KELLY K, CROWLEY J, BUNN PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A southwest oncology group trial[J]. Journal of Clinical Oncology, 2001, 19(13): 3210–3218. doi: 10.1200/JCO.2001.19.13.3210
    SANDLER A, GRAY R, PERRY M C, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. New England Journal of Medicine, 2006, 355(24): 2542–2550. doi: 10.1056/NEJMoa061884
    MCNAMARA M, SWEENEY C, ANTONARAKIS E S, et al. The evolving landscape of metastatic hormone-sensitive prostate cancer: A critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation[J]. Prostate Cancer and Prostatic Diseases, 2018, 21(3): 306–318. doi: 10.1038/s41391-017-0014-9
    ROBINET G, BARLESI F, FOURNEL P, et al. Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: A phase II randomized study[J]. Targeted Oncology, 2007, 2(2): 63–71. doi: 10.1007/s11523-007-0042-9
    ANGELOPOULOU A, KOLOKITHAS-NTOUKAS A, FYTAS C, et al. Folic acid-functionalized, condensed magnetic nanoparticles for targeted delivery of doxorubicin to tumor cancer cells overexpressing the folate receptor[J]. ACS Omega, 2019, 4(26): 22214–22227. doi: 10.1021/acsomega.9b03594
    TEDESCO-SILVA H, PASCUAL J, VIKLICKY O, et al. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: An analysis from the randomized TRANSFORM study[J]. Transplantation, 2019, 103(9): 1953–1963. doi: 10.1097/TP.0000000000002626
  • 加载中
图(5) / 表(2)
计量
  • 文章访问数:  2662
  • HTML全文浏览量:  1011
  • PDF下载量:  252
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-10-29
  • 修回日期:  2020-01-20
  • 网络出版日期:  2020-02-27
  • 刊出日期:  2020-06-22

目录

    /

    返回文章
    返回